Abattis Bioceuticals Corp.

OTC: ATTBF · Healthcare · Medical - Pharmaceuticals

Canadian filerHQ Vancouver, BCReports USD

#968 of 1,394 Healthcare companies by revenuetop-decile growth

EA Score

——

FH —DQ —GM —SS 40

v0.1 · 5/100 weight · pillars only

↑ revenue growth (YoY), return on assets · ↓ market scale, disclosure history

Methodology →

Revenue TTM

$269.0k

Rev growth YoY (TTM)

+4005.8%

Net income (FY)

-$2.3M

Employees

Market cap

$14.3k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$268.9k356.9k CAD2019

Net income-$2.3M-3.0M CAD2019

Operating income-$3.0M-4.0M CAD2019

Total assets$14.5M19.3M CAD2019

Liabilities$6.5M8.6M CAD2019

Equity$8.4M11.1M CAD2019

Revenue trend

FY2017 – FY2019 · USD

FY17

$6.5k

FY18

$268.9k

FY19

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Abattis Bioceuticals Corp. booked $268.9k in FY2019 revenue, growing 4024% year over year — faster than 99% of Healthcare companies we track, at a -852.4% net margin.

Peers · Healthcare

Wellness Center USA, Inc.——MPX International Corp.——CERo Therapeutics Holdings, Inc.——Golden Developing Solutions, Inc.——

Key facts

CEORobert G. Goodall

SectorHealthcare

IndustryMedical - Pharmaceuticals

HeadquartersVancouver, BC

ExchangeOTC: ATTBF

Employees48

IPO date2014-05-29

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.